by Raynovich Rod | Jul 30, 2015 | Biopharmaceuticals
Update-1 Stealth End of Month Rally Stops Biotech Slide IBB up 3.4% In July and up 1% on Last Day Stocks roared out of the box on Friday but could not hold and ended flat. NASDAQ Up 2.3% for July. Most biotech stocks were green and momentum players came back in to...
by Raynovich Rod | Jul 16, 2015 | Biopharmaceuticals
Biotech Stocks More Subdued- as of Mid-Day 7/20 Trading Biotechnology stocks are taking a rest today after a torrid five days that saw the XBI up 7.31%, FBT up 6.19% and the IBB up 6.65%. Moreover on Friday 7/17 the trading in six or more biotech small caps made the...
by Raynovich Rod | Jul 14, 2015 | 2024 Rayno Biopharmaceuticals Portfolio
Rayno Top Winners YTD 10/12/15 Fibrocell Science (FCSC) up 69% Clovis Oncology (CLVS) up 61.6% Regeneron (REGN) up 28.4% Seattle Genetics (SGEN) up 21.3% Gilead Sciences (GILD) up 5.6% —— Rayno Top Losers YTD Biogen Idec (BIIB) down 21.5%….down again...
by Raynovich Rod | Jun 30, 2015 | 2024 Rayno Biopharmaceuticals Portfolio
Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI Biotech ETF continues to be the sector ETF leader up...
by Raynovich Rod | May 20, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 uniQure up on deal with BMY (CURE) Cardiovascular Deal with Bristol Myers (BMY) The closing of the uniQure deal with Bristol Myers triggered a $50M payment. Three collaboration targets in cardiovascular and future areas. The stock is up 81% YTD but off its...
by Raynovich Rod | May 8, 2015 | 2024 Rayno Biopharmaceuticals Portfolio
Jobs Report Drive Stocks Higher-DOW Up 1.5% Stocks moved higher on the “goldilocks” job report which showed a gain of 223k added in April. The jobs number was too high to raise concerns about an increase in rates but not too bullish because overall...
by Raynovich Rod | May 1, 2015 | Biopharmaceuticals
Biotech Bounce-Caution on New Positions IBB up 2% at 340 support level Most biotech stocks are green as of early trading on May 1. Although the sector has taken a beating since April 23 most ETFs and funds are outperforming the market year to date up more than 10%. As...
by Raynovich Rod | Apr 28, 2015 | Biopharmaceuticals
Gilead (GILD) Gilead Beats Q1 Estimates: $7.4B Sales HCV , EPS $2.94, stock up 2% after hours XBI Down Another 4% Down 12.84% in Five Days Weak Tape and Sell-Off Continues…4/30…NASDAQ at 4991 XBI down 1.6% now at 2/24 lows at 212 High fliers hit with...
by Raynovich Rod | Apr 24, 2015 | Biopharmaceuticals
Can Biotech Leadership Continue Up 20% YTD Biotech stocks were roughed up on Friday with a potential market rotation out of healthcare into technology. The XLK Technology SPDR was up 4% for the week compared to only 2% for the IBB. The XLK holds large cap stocks such...
by Raynovich Rod | Apr 16, 2015 | 2024 Rayno Biopharmaceuticals Portfolio
Biotech Sector Moves Up In Tiny Steps Risk Remains On AACR Next Week Will Move Cancer Stocks Biotech indices and ETFs are trying to hit new highs but momentum is easing and trading is choppy. Nonetheless we are moving up from the brief correction near channel lows at...